Omeros sells global rights to zaltenibart to Novo Nordisk for up to $2.1B

OMEROS CORP

Upfront $240M cash plus near-term milestones total $340M; up to $2.1B including development & sales milestones plus tiered royalties.
Novo Nordisk gains exclusive global rights to develop and commercialize MASP-3 inhibitor zaltenibart in all indications.
Omeros will use part of upfront to repay $67.1M term loan; remaining funds support narsoplimab approval and preclinical pipeline.
Transaction expected to close Q4 2025, subject to HSR clearance and customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.